MedTrace Logo

Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis

NCT02101333 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-08-19

No results posted yet for this study

Summary

First-line tocilizumab treatment during 6 months could permit rapid steroid-tapering and induction of remission in Takayasu arteritis (TA).

Conditions

  • TAKAYASU ARTERITIS

Interventions

DRUG

Tocilizumab

intravenous injection 8 mg/kg, monthly during 6 months

Sponsors & Collaborators

  • Chugai Pharmaceutical

    collaborator INDUSTRY

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Olivier FAIN · médecine interne - St Antoine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
77 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-10
Primary Completion
2018-12-10
Completion
2019-02-01

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02101333 on ClinicalTrials.gov